Status:
COMPLETED
Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
Misr International University
Conditions:
Corona Virus Disease 19 (Covid19)
Corona Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine "NAC" in COVID 19 patients.
Detailed Description
This is a phase 3 trial enrolling subjects with newly diagnosed Corona virus disease 2019 ( COVID-19) infection who are classified as moderate cases and require hospitalization. Patients meeting eligi...
Eligibility Criteria
Inclusion
- Adults aged more than 18 years
- Documented COVID-19 infection (either performed on site or documented external report), only moderate cases will be included
Exclusion
- Known allergy or hypersensitivity to NAC
- Pregnancy
- Critically ill or mechanically ventilated patients
Key Trial Info
Start Date :
March 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04792021
Start Date
March 9 2021
End Date
April 1 2022
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al Assema Hospital
Cairo, Egypt